Nagasaki Toshiki, Inaba Masaaki, Yamada Shinsuke, Kumeda Yasuro, Hiura Yoshikazu, Nishizawa Yoshiki
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka-city 545-8585, Japan.
Biomed Pharmacother. 2007 Sep;61(8):482-7. doi: 10.1016/j.biopha.2007.04.004. Epub 2007 May 21.
Subclinical hypothyroidism affects 5-15% of the population and is associated with increased cardiovascular morbidity, although this is controversial. We recently reported a significant increase in brachial-ankle pulse wave velocity (baPWV), a parameter of arterial stiffening and an independent predictor for cardiovascular events, in subclinical hypothyroidism. The current study was performed to assess changes in enhanced baPWV in subclinical hypothyroidism during normalization of thyroid function.
Forty-two subclinical hypothyroid patients (male/female ratio 8/34) were monitored for changes in baPWV before and after levothyroxine (L-T(4)) replacement therapy.
After attaining euthyroidism, 59.5% and 40.5% of the patients showed reduction and increase of baPWV, respectively. Baseline baPWV and pulse pressure were significantly higher in patients with reduced baPWV (1940.3+/-126.4 vs. 1726.4+/-110.4 cm/s, P=0.046; 62.1+/-3.1 vs. 50.7+/-3.7 mmHg, P=0.026, respectively). Baseline baPWV was significantly correlated with baseline pulse pressure in both groups, but the change in baPWV was significantly correlated with baseline pulse pressure only in patients with reduced baPWV (rho=-0.522, P=0.046). The male/female ratio was significantly lower in patients with reduced baPWV (4/21 vs. 7/10), and systolic, diastolic and pulse pressures and pulse rate decreased significantly only in patients with reduced baPWV.
Our results suggest that L-T(4) replacement therapy may be especially beneficial in female subclinical hypothyroid patients with high baseline baPWV and pulse pressure. The beneficial effects of L-T(4) replacement therapy in decreasing arterial stiffening and thus preventing cardiovascular disease might be limited to this sub-population.
亚临床甲状腺功能减退影响5% - 15%的人群,且与心血管疾病发病率增加相关,尽管这一点存在争议。我们最近报道,在亚临床甲状腺功能减退患者中,肱踝脉搏波速度(baPWV)显著增加,baPWV是动脉僵硬度的一个参数,也是心血管事件的独立预测指标。本研究旨在评估甲状腺功能正常化过程中亚临床甲状腺功能减退患者增强型baPWV的变化。
对42例亚临床甲状腺功能减退患者(男/女比例为8/34)在左甲状腺素(L-T4)替代治疗前后监测baPWV的变化。
甲状腺功能恢复正常后,分别有59.5%和40.5%的患者baPWV降低和升高。baPWV降低的患者基线baPWV和脉压显著更高(分别为1940.3±126.4 vs. 1726.4±110.4 cm/s,P = 0.046;62.1±3.1 vs. 50.7±3.7 mmHg,P = 0.026)。两组患者基线baPWV均与基线脉压显著相关,但仅在baPWV降低的患者中baPWV的变化与基线脉压显著相关(ρ = -0.522,P = 0.046)。baPWV降低的患者中男/女比例显著更低(4/21 vs. 7/10),且仅在baPWV降低的患者中收缩压、舒张压、脉压和脉率显著下降。
我们的结果表明,L-T4替代治疗可能对基线baPWV和脉压较高的女性亚临床甲状腺功能减退患者特别有益。L-T4替代治疗在降低动脉僵硬度从而预防心血管疾病方面的有益作用可能仅限于这一亚组人群。